Member Info for Candid

The data and experience gained over the years of research will prove valuable going forward.
This drug has been in development for 15 years now and has had other successful trials.
As mentioned at the presentation yesterday, the treatment is expected to be used not only for Covid-19 but various other serious respiratory diseases.

demand v supply of shares is looking good, Acacia selling pressure is over now and remaining holders are mainly the directors, Leonard Licht and Landsdowne.
I would think funds, especially healthcare funds are keen to load up here now.

Also the COPD trial results to look forward to. It was mentioned at today’s call that the COPD results will be out next month and Richard did sound very confident when stating this.

Further key points from the broker note:

“These results, given the quality of the data, substantially de-risk this clinical programme.
Bringing SNG001 to market, will depend on the regulator’s view of the drug and the potential for use, for example in the US under an Emergency Use Authorization (EUA) from the FDA.
Part of the fundraise in April 2020 was allocated to ensuring that the manufacturing supply chain was ramped up. With sufficient product to meet its current clinical trial needs, Synairgen expects to be in a position to produce tens of thousands of doses per month by August, with the potential to provide up to 1m doses by the end of 2020.”

This morning’s note included the following valuation update, which is at the conservative end:

“We raise our target price to 360p (sum-of-the-parts rNPV). It assumes a 50% chance of SNG001 reaching the market. However, it is within the realms of possibility that Synairgen will receive orders from governments ahead of the winter flu season and potential second wave of COVID-19 infections. Based on pricing points for Rebif and Avonex and Gilead’s remdesivir ($2-3,000 per treatment) and the prospect of Synairgen being able to supply up to 1m doses by the end of 2020, it is not inconceivable that an order book of $2-3bn could be generated by the year-end, which would imply a valuation substantially higher than 360p (c.£0.5bn market cap).”

I’ve just read the note this morning and have topped up, very positive write-up

GLA

Just added to my holding following the news out at Verona Pharma, they are up 125% today having raised $200m for a phase III COPD trial, they have an inhaled nebuliser treatment for COPD, (not Interferon), but it just goes to show how much COPD treatments are in demand right now..

could also be in line for one of the tipsters

The earlier £12k buy today has likely perked this up followed by more buys. I wouldn’t be surprised to see further news tomorrow or next week.
News could be on the Japan railway project or even contract wins in US, that would set this up nicely.

Potentially very significant news, does anyone have any more info about Merck’s testing of Rebif for Covid-19?
I’m no scientist but this looks like the same formulation as SNG’s Interferon beta 1a (IFN-ß1a) SNG 001.
SNG is using an inhaled formulation, while Merck is presumably using an injected formulation.

clinical trial data will be shared as soon as it’s been reviewed and signed off. The real drag on the shareprice over the past few weeks has been Acacia selling and they have 11,266,293 shares to go

Directors and management hold over 40% of the company

Hi WG, yes indeed looks like a good year for MNO. The stand-out for me from today’s Esri announcement is: “agreement to formalise joint solution efforts around the world”

A major global company such as Esri has many clients already and more to come.

decent rise, most likely on the back of Nickel price moving up. Some decent forecasts for Nickel starting to emerge, and this is exactly what HZM needs to secure financing.

“UBS last week published an updated price forecast for the metal which is sitting around $5.70 a pound. The forecast by the bank is for the price to reach $7/lb next year and $8/lb in 2022”

Partnering with Esri really highlights MNO’s potential, here’s a quick overview of what Esri are doing in the railway asset space:
https://www.esri.com/library/brochures/pdfs/a-smarter-view-of-rail.pdf

true, when you can sell but can’t buy, it means lack of supply. MMs want your shares

Just realised that MNO’s technology can be applied not only for railways globally but for subway transportation as well

Partnering with Esri is a route for MNO to win new contracts in the US market.
Esri already has major rail clients in US and globally.

Two major announcements:
1) ARTC rail confirming that they have undertaken the appropriate engineering acceptance activities that demonstrate that the Corridor Technology platform meets engineering accuracy and safety requirements , to replace the manual method of surveying rail track infringements and track clearances.
2) Partnership with Esri Inc , the global leader in Geographic Information Systems with 40% global market share. This is a multi-billion dollar US tech company, privately held.

MNO’s technology is now getting some serious recognition in the market.